LEADER 02378nam  22005771  450 
001 9910463771903321
005 20200520144314.0
010   $a1-60805-747-X
035   $a(CKB)2670000000402537
035   $a(EBL)1336319
035   $a(OCoLC)855504888
035   $a(SSID)ssj0001127419
035   $a(PQKBManifestationID)11669035
035   $a(PQKBTitleCode)TC0001127419
035   $a(PQKBWorkID)11150175
035   $a(PQKB)10182177
035   $a(MiAaPQ)EBC1336319
035   $a(Au-PeEL)EBL1336319
035   $a(CaPaEBR)ebr10762668
035   $a(EXLCZ)992670000000402537
100   $a20130810d2013      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aErythropoietic stimulating agents /$feditor, Elisio Costa; co-editors, Flavio Reis and Alice Santos-Silva
210  1$aOak Park, Illinois :$cBentham Science Publishers,$d2013.
215   $a1 online resource (306 p.)
225  0$aFrontiers in drug discovery ;$vv. 1
300   $aIncludes index.
311   $a1-60805-748-8 
327   $aCover; TItle; EUL; Contents; Foreword; Preface; List of Contributors; Chapter 01; Chapter 02; Chapter 03; Chapter 04; Chapter 05; Chapter 06; Chatper 07; Chapter 08; Chatper 09; Chapter 10; Chapter 11; Chapter 12; Chapter 13; Chapter 14; Index; Bak Cover
330   $aThis volume includes a revision of articles on erythropoiesis and EPO gene regulation, microRNAs and their potential contribution to the development of new therapeutic strategies, animal models for studying kidney disease-associated anemia as well as benefits/risks of ESA therapy. The biological effects of new ESA molecules, heparin-binding erythropoietin and of pHBSP, and the potential applications of ESA, are also elicited in this volume.
410  0$aFrontiers in Drug Discovery
606   $aErythrocytes
606   $aErythropoiesis$xRegulation
608   $aElectronic books.
615  0$aErythrocytes.
615  0$aErythropoiesis$xRegulation.
676   $a612.111
701   $aCosta$b Elisio$0922583
701   $aReis$b Fla?vio$0922584
701   $aSantos-Silva$b Alice$0922585
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910463771903321
996   $aErythropoietic stimulating agents$92070180
997   $aUNINA